Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Ranbaxy and Caraco, U.S. FDA Cracks Down On Lupin, Finds Lapses At Its Mandideep Site

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Continuing with its crackdown on manufacturing sites of large Indian generic companies, U.S. FDA issued a Form 483 for 15 deficiencies at Lupin's manufacturing site at Mandideep situated in central India
Advertisement

Related Content

14 Months After U.S. FDA Charged India's Lupin, Manufacturing Facility At Mandideep Cleared
14 Months After U.S. FDA Charged India's Lupin, Manufacturing Facility At Mandideep Cleared
U.S. FDA Issues Warning Letter To Lupin Citing Manufacturing Deficiencies; Warns Products Will Not Be Approved Until Corrective Action
U.S. FDA’s International Offices To Be Fully Staffed By End Of Summer
FDA’s International Offices To Be Fully Staffed By End Of Summer
Cipla’s Manufacturing Units In India Under U.S. FDA Lens; Inspectional Observations Issued
U.S. FDA To Open India Office In December
After Ranbaxy, U.S. FDA Hauls Up Caraco Pharma for QC Issues; May Withhold Future Drug Approvals
After Ranbaxy, U.S. FDA Hauls Up Caraco Pharma for QC Issues; May Withhold Future Drug Approvals
Ranbaxy Woes Continue With 30-plus Product Import Alert
Advertisement
UsernamePublicRestriction

Register

SC067159

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel